SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
SI-BONE, Inc. CEO and director Laura Francis reported that The David & Laura Joint Rev Tr sold 38,006 common shares on October 12, 2026, at a weighted-average price of $20.0498 per share. The sale was made under a Rule 10b5-1 trading plan dated May 21, 2026. The trust held 379,256 shares following the transaction. Francis also reported 368,129 directly held common shares, including 355,697 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. is named as issuer in a Form 144 notice listing 38,006 common shares for sale for the account of David & Laura Francis Joint Rev Tru/A Dtd January 3, 2003, with Morgan Stanley Smith Barney LLC listed as broker. The stated aggregate market value is $736,176.22; shares outstanding were 44,818,575 as of October 12, 2026. The remarks say the securities were acquired upon restricted stock unit vesting between May 15, 2021, and November 15, 2025, and that sales executed October 12, 2026, are being reported. Laura Francis signed the notice; a past-sales entry lists 14,956 shares for her on August 17, 2026, for $279,064.67.
SI-BONE, Inc. SVP, Ops & Adm/Chief Legal Ofr Michael A. Pisetsky reported selling 3,133 shares of common stock on October 2, 2026, across three sales: 1,300 at $18.2033, 1,799 at $18.1418, and 34 at $18.1400 per share. The first two prices are weighted averages of multiple trades. The sales were required to cover tax withholding obligations tied to restricted stock unit vesting and were not discretionary trades.
SI-BONE, Inc.'s Chief Op & Financial Officer, Anshul Maheshwari, reported three common-stock sales: 1,560 shares at $18.1674 and 1,758 shares at $18.1933 on October 2, 2026, and 1,731 shares at $19.5000 on October 5, 2026. The October 2 sales covered tax withholding obligations tied to restricted stock unit vesting; they were not discretionary and were executed in multiple trades at prices from $18.05 USD to $18.45 USD, with the reported prices reflecting weighted averages. The October 5 sale was effected under a Rule 10b5-1 trading plan dated December 17, 2025. A footnote associated with the October 5 transaction says the post-transaction amount includes 160,823 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. director Jeffrey W. Dunn exercised options covering 20,000 shares at an exercise price of $4.68 per share on October 1, 2026, and sold 20,000 common shares at a weighted average price of $18.47 per share. The sale was made under a Rule 10b5-1 trading plan dated May 7, 2025; sale prices ranged from $18.28 to $18.96 per share. The option row lists 66,260 options following the transaction. The report also lists 81,073 common shares held by The Jeffrey W. Dunn Living Trust Dated May 17, 2012.
SI-BONE, Inc. officer Anshul Maheshwari reported a proposed sale of 1,731 common shares, with an aggregate market value of $31,296.48 and an approximate sale date of October 5, 2026; Morgan Stanley Smith Barney LLC is listed as broker and NASDAQ as the exchange. Recent reported sales include 3,318 shares for $60,376.98 on October 2, 2026 and a 10b5-1 sale of 11,636 shares for $233,971.66 on August 24, 2026.
SI-BONE, Inc. (SIBN) reported two main developments: a short extension of its headquarters lease and a targeted product recall. The company and BIXBY SPE FINANCE 11, LLC signed a Fourth Amendment to extend the lease for its 21,848-square-foot Santa Clara headquarters for one month from October 1, 2026 through October 31, 2026, at base rent of $43,696 per month, with SI-BONE continuing to pay its share of operating expenses and taxes through the new expiration date.
Separately, SI-BONE initiated a voluntary recall of 98 iFuse TORQ implants whose tube packaging, manufactured between May 4 and May 15, 2026, did not consistently meet acceptance criteria as a sterile barrier, potentially raising infection risk. Two of these implants had already been used; the company notified the implanting physicians and, as of this report, has received no infection or adverse event reports related to those procedures. SI-BONE filed a correction and removal report with the FDA on August 31, 2026 and recommended that the action be classified as a Class II recall. Approximately 3,900 implants are expected to be repackaged and re-sterilized, including recalled and quarantined inventory, largely still under company or manufacturer control. SI-BONE currently expects to record an aggregate gross charge of up to $150,000 in cost of goods sold across the third and fourth quarters and intends to seek recovery of these costs from the tube manufacturer, though recovery is not assured. The company states it does not believe third-quarter revenue or its ability to supply implants will be otherwise affected and plans to update investors on the financial impact with its third-quarter results.
SI-BONE, Inc. (SIBN) director Jeffrey W. Dunn reported exercising options for a total of 20,000 shares of common stock at an exercise price of $4.68 per share on September 1, 2026, and selling the same 20,000 shares at a weighted-average price of $18.908 per share pursuant to a Rule 10b5-1 trading plan. He also reports 81,073 shares held indirectly by The Jeffrey W. Dunn Living Trust and holdings that include 10,957 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN) reported that Chief Executive Officer and director Laura Francis, through The David & Laura Joint Rev Tr., sold 25,972 shares of common stock on 2026-08-24 at a weighted-average price of $20.1215 per share, in transactions ranging from $20.00 to $20.24, pursuant to a Rule 10b5-1 trading plan dated May 21, 2026. Following this sale, the trust holds 291,491 shares indirectly, and Francis also has 493,900 shares held directly, including 355,697 shares issuable upon settlement of restricted stock units, each RSU representing a right to receive one share of common stock.
SI-BONE, Inc. (SIBN) reported that Anshul Maheshwari, its Chief Operating & Financial Officer, sold 11,636 shares of common stock on 2026-08-24 at a weighted-average price of $20.1075 per share under a Rule 10b5-1 trading plan dated December 17, 2025. After this sale, Maheshwari directly holds 223,284 shares, which include 167,604 shares issuable upon settlement of restricted stock units.